$HALO (HALOZYME THERAPEUTICS) — 8-K: Halozyme prices upsized $1.3 billion convertible notes at 1.50% due 2033

Halozyme priced $1.3 billion of 1.50% convertible senior notes due 2033, upsized from $1.05 billion, with a 13-day option for purchasers to buy up to an additional $200 million. Initial conversion price is approximately $139.84 per share, a 27.5% premium to the $109.68 closing price on September 17, 2026. Capped call transactions have an initial cap price of approximately $208.39 per share, a 90.0% premium. The offering is expected to close September 22, 2026.

Halozyme priced $1.3 billion of 1.50% convertible senior notes due 2033, upsized from $1.05 billion, with a 13-day option for purchasers to buy up to an additional $200 million. Initial conversion pri